Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody.

Dominguez, G.,Condamine, T. C.,Mony, S.,Hashimoto, A.,Wang, F.,Liu, Q.,Forero, A.,Bendell, J. C.,Witt, R.,Hockstein, N.,Kumar, P.,Gabrilovich, D.; Clin. Cancer Res.. 2016 Dec 15.

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.

Grilley-Olson JE, Bedard PL, Fasolo A, Cornfeld M, Cartee L, Razak ARA, Stayner L, Wu Y, Greenwood R, Singh R, Lee CB, Bendell J, Burris HA, Del Conte G, Sessa C, Infa...; Invest New Drugs. 2016-12-01.

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after ...

Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, Alcindor T, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang PA, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, T...; Ann. Oncol.. 2016-12-01.